|By JCN Newswire||
|May 27, 2014 02:14 AM EDT||
Tokyo, May 27, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it will launch its new carbonated supplement drink Chocola BB Sparkling Salty Natsumikan* Flavor, classified as a Food with Nutrient Function Claims, in Japan on Monday, June 2.
Chocola BB Sparkling Salty Natsumikan Flavor is a new carbonated supplement drink classified by the Japanese Ministry of Health, Labour and Welfare as a Food with Nutrient Function Claims (Niacin). The drink contains five ingredients that help bring out women's beauty from within, including 1,500 mg of vitamin C in addition to niacin, vitamin B1, B6 and iron, and it also contains 56 mg of sodium which becomes increasingly vital for sodium replenishment during summer. It features the clean and refreshing taste of natsumikan, which is popular as a fruit with the image of summer, as well as a low calorie count of just 24 kcal per bottle. As a delicious and easy way to replenish sodium, the drink is designed to address the needs of women who want to stay energetic all summer long.
Chocola BB Sparkling Salty Natsumikan Flavor is the newest member of the Chocola BB Sparkling series including Chocola BB Sparkling Grapefruit & Peach Flavor, Chocola BB Sparkling White Grape Flavor and Chocola BB Sparkling Vitamin Kyutto Lemon Flavor, all of which have been well-received since launch.
Eisai will continue to provide the Chocola BB family of products to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.
*Natsumikan: A yellowish orange citrus fruit native to Japan
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Jul. 1, 2015 01:15 PM EDT Reads: 2,129
Jul. 1, 2015 12:54 PM EDT Reads: 318
Jul. 1, 2015 12:15 PM EDT Reads: 2,017
Jul. 1, 2015 12:00 PM EDT Reads: 1,966
Jul. 1, 2015 11:45 AM EDT Reads: 979
Jul. 1, 2015 11:30 AM EDT Reads: 716
Jul. 1, 2015 11:30 AM EDT Reads: 2,219
Jul. 1, 2015 11:30 AM EDT Reads: 933
Jul. 1, 2015 11:10 AM EDT Reads: 469
Jul. 1, 2015 11:00 AM EDT Reads: 492
Jul. 1, 2015 11:00 AM EDT Reads: 918
Jul. 1, 2015 10:30 AM EDT Reads: 2,103
Jul. 1, 2015 10:30 AM EDT Reads: 750
Jul. 1, 2015 09:45 AM EDT Reads: 1,917
Jul. 1, 2015 09:32 AM EDT Reads: 473